Lixte Biotechnology (NASDAQ:LIXT) Releases Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) announced its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share for the quarter, FiscalAI reports.

Lixte Biotechnology Price Performance

NASDAQ LIXT traded up $0.12 during mid-day trading on Friday, hitting $5.16. The company’s stock had a trading volume of 149,390 shares, compared to its average volume of 60,573. Lixte Biotechnology has a 52-week low of $0.64 and a 52-week high of $6.26. The stock’s fifty day simple moving average is $3.43 and its two-hundred day simple moving average is $3.64. The firm has a market capitalization of $59.96 million, a P/E ratio of -4.57 and a beta of 1.04.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lixte Biotechnology in a report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Lixte Biotechnology

A number of large investors have recently added to or reduced their stakes in the company. Axxcess Wealth Management LLC acquired a new stake in Lixte Biotechnology during the 4th quarter valued at $54,000. XTX Topco Ltd acquired a new stake in Lixte Biotechnology during the 4th quarter valued at $57,000. Federation des caisses Desjardins du Quebec grew its holdings in Lixte Biotechnology by 83.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after purchasing an additional 42,530 shares in the last quarter. DRW Securities LLC grew its holdings in Lixte Biotechnology by 11.6% during the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Lixte Biotechnology by 47.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after purchasing an additional 34,350 shares in the last quarter. 5.10% of the stock is owned by institutional investors and hedge funds.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.